MRK: Approves KEYTRUDA
European Commission approves KEYTRUDA plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MRK: EU Approves Keytruda
The European Union approves Merck's Keytruda in combination with Padcev for adults with resectable muscle-invasive bladder cancer
MRK Gets EU Approval
MRK's KEYTRUDA and Padcev approved by European Commission for treatment of muscle-invasive bladder cancer